TriSalus Life Sciences (NASDAQ:TLSIW) focuses on transforming the way solid tumor cancers are treated, with a keen emphasis on pancreatic and liver cancers. The company is committed to improving patient outcomes by integrating Pressure-Enabled Drug Delivery (PEDD) with immunotherapies to overcome the physical barriers that have historically limited effective treatment delivery to solid tumors. TriSalus’s operations are deeply rooted in innovation and research, aiming to develop therapies that can make a significant difference in patients’ lives. Their projects include advanced clinical trials and the development of proprietary drug delivery technologies designed to enhance the efficacy of existing cancer treatments. The objective of TriSalus is not only to extend the lifespan but also to improve the quality of life for patients fighting these challenging diseases.